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Abstract
Silymarin, an extract from seeds of Silybum marianum, is used by 8-33% of patients to self-treat
chronic viral hepatitis C in the United States. Studies in humans and rodents suggest that biliary
excretion of glucuronide and sulfate conjugates is the major route for silymarin’s elimination. To
determine the role of multidrug resistance associated-protein 2, Mrp2 (Abcc2), in the biliary excretion
of silymarin, the hepatobiliary disposition of the six major silymarin flavonolignans was studied
using isolated perfused livers (IPRLs) from wild-type (WT) and Mrp2-deficient (TR-) Wistar rats.
For all flavonolignans, approximately 96% of the dose was cleared from perfusate within 30 min in
both WT and TR- livers, and < 5% of parent was recovered in bile or perfusate by the end of the
perfusion. In WT livers, the percentage of dose excreted as conjugates into bile varied for each
flavonolignan (silychristin, 51.6% ± 9.3; silydianin, 101.5% ± 28.3; silybin A, 21.0% ± 8.3; silybin
B, 31.7% ± 13.2; isosilybin A, 50.5% ± 23.6; isosilybin B, 42.8% ± 19.3). Among the flavonolignans,
only silydianin was primarily glucuronidated and almost completely recovered in bile. In TR- livers,
biliary excretion of flavonolignan conjugates was reduced 80-92%, with 30-83% of each
flavonolignan conjugate recovered in perfusate compared to only 5-30% at 90 min. Biliary excretion
of glucuronide and sulfate conjugates of all flavonolignans were reduced by 94-98% and 73-84%
respectively, in TR- IPRLs. These data indicate a primary role for Mrp2 in the biliary elimination of
silymarin flavonolignan conjugates.
Silymarin, a herbal extract commonly known as milk thistle, is used approximately by 8-33%
of patients in the United States to self-treat chronic hepatitis C virus (HCV) (Seeff et al.,
2008). Silymarin is a complex mixture of six major flavonolignans (silybin A and B; isosilybin
A and B; silychristin; silydianin), the most common class of flavonoids in milk thistle extract,
as well as other polyphenolic compounds (Kim et al., 2003). Silybin A and silybin B are the
most abundant flavonolignans in milk thistle extracts and are used to standardize commercial
preparations. Silymarin is hepatoprotective in laboratory animals to the toxic effects of carbon
tetrachloride, ethanol and acetaminophen (Crocenzi and Roma, 2006). Recently, two
independent laboratories have demonstrated the antiviral effects of silymarin in HCV replicon
assays (Polyak et al., 2007; Bonifaz et al., 2007). However, the beneficial effects of silymarin
in liver disease have not been established due to inconsistencies in results obtained from several
randomized clinical trials that may reflect various trial designs and the use of different
formulations (Mayer et al., 2005). In addition, recent data suggest that the pharmacokinetics
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of silymarin is influenced by the type and stage of liver disease (Schrieber et al., 2008a). While
the precise pathways of metabolism and excretion have not been identified, limited data from
human and animal studies suggest that flavonolignans primarily undergo rapid and extensive
phase II metabolism and biliary excretion (Schandalik et al., 1992; Morazzoni et al., 1992;
Morazzoni et al., 1993).
In rats and humans, silymarin is characterized by low bioavailability, rapid conjugation and
biliary excretion of silymarin and flavonolignan conjugates. In rats, only 2% of the orally
administered dose of silymarin was recovered in the bile unchanged while the remaining was
recovered as sulfate and glucuronide conjugates (Morazzoni et al., 1993). However, the
transport proteins primarily responsible for biliary excretion of silymarin and its metabolites
have not been identified.
Silymarin is a potent inhibitor of breast cancer resistance protein (Bcrp) in MCF-7 cells (Zhang
et al., 2004). Additionally, it has been shown that silymarin can inhibit P-glycoprotein-
mediated efflux of digoxin in human intestinal Caco-2 cells (Zhang and Morris, 2003).
Multidrug resistance associated-protein, Mrp2, which is expressed in the liver, gut, kidney,
and brain mediates the biliary elimination of many flavonol conjugates (Hoffmann and
Kroemer, 2004; Cermak and Wolffram, 2006). Mrp2 (Abcc2) is a member of the ATP-binding
cassette (ABC) superfamily of membrane transporters which is responsible for the biliary
excretion of organic anions, glucuronide, glutathione and sulfate conjugates of endogenous
compounds as well as xenobiotics (Zamek-Gliszczynski et al., 2005; Zamek-Gliszczynski et
al., 2006a; König et al., 1999). The specific role of each of these canalicular transport proteins
in the excretion of silymarin and its conjugates has not been established.
The isolated perfused rat liver (IPRL) is a valuable and commonly employed ex vivo model
for studying the metabolism and transport mechanisms involved in the hepatobiliary
disposition of drugs. This model permits exposure of the liver to different test substances,
allows repeated sampling to determine disposition of parent compound and metabolites in
perfusate and bile, and is independent of the influence of other organ systems (Gores et al.,
1986). Compared with isolated hepatocytes, hepatic architecture, cell polarity and bile flow
are preserved in the isolated perfused liver (Jansen et al., 1985), making this a useful model to
study metabolism and biliary excretion of various substances. The IPRL technique has been
used successfully in various genetic animal models to investigate the precise mechanisms of
hepatobiliary disposition of drugs. For example, a number of studies have employed IPRL to
examine the role of Mrp2 utilizing TR- rats which are mutant rats that lack functional Mrp2 at
the canalicular membrane (Jansen et al., 1985; McDonagh et al., 2001), similar to patients with
Dubin-Johnson syndrome (Paulusma et al., 1997). Such studies have demonstrated marked
reduction in biliary excretion of glucuronide and sulfate conjugates of drugs and other
compounds in TR- rats, implying that Mrp2 is responsible for the biliary excretion of organic
anions.
The purpose of this study was to determine the role of Mrp2 in the biliary excretion of the six
major silymarin flavonolignans and their conjugates by using IPRLs from Mrp2-competent
(wild-type) and Mrp2-deficient (TR-) Wistar rats. Pharmacokinetic parameters were
determined for both the perfusate and bile compartments.
Materials and Methods
Chemicals
Silymarin (SIL), dimethyl sulfoxide (DMSO), β-glucuronidase (EC 3.3.1.3.1; type B-10 from
bovine liver), sulfatase (EC3.1.6.1; type H-1 from Helix pomatia), D-saccharic acid 1,4-lactone
(D-SL), naringenin, and taurocholate were purchased from Sigma-Aldrich (St. Louis, MO).
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Reference standards for silychristin (SC) were obtained from ChromaDex (Santa Ana, CA),
and silydianin (SD) was purchased from U.S. Pharmacopoeia (USP; Rockville, MD). The
composition of silybin (Silibinin, Sigma-Aldrich, St. Louis, MO) was confirmed to be a mixture
of silybin A (SA) and silybin B (SB) by LC-ESI-MS and the specific contents of SA and SB
were analyzed to be 48% and 52%, respectively. Isosilybin A (ISA) and isosilybin B (ISB)
reference standards were obtained as a generous gift from Ulrich Mengs (Madaus GmbH,
Germany). The purity of all six silymarin flavonolignan standards was between 97- 99%. All
other chemicals and reagents were of analytical grade and available from commercial sources.
Animals
Male Wistar rats (200-250 g) from Charles River Laboratories, Inc. (Raleigh, NC), and male
TR- rats bred in our facility (275-300 g; breeding stock obtained from Dr. Mary Vore,
University of Kentucky, Lexington, KY) were used as liver donors for perfused liver studies.
Retired male Wistar breeder rats (400-500 g; Charles River Laboratories, Inc.) were used as
blood donors. Rats were housed in an alternating 12-h light/dark cycle with rat chow and water
provided ad libitum. All animals were allowed to acclimate for at least one week before
experimentation. Rats were anesthetized with ketamine/xylazine (60:12 mg/kg i.p). The
Institutional Animal Care and Use Committee at the University of North Carolina approved
all animal procedures.
Liver Perfusion Studies
Recirculating IPRL studies were conducted with wild-type (WT) and TR- rat livers as described
previously (Brouwer and Thurman, 1996). Briefly, after portal vein and bile duct cannulation,
livers were perfused in situ with oxygenated buffer (pH 7.4). Livers were removed from the
body cavity and placed in a humidified perfusion chamber heated to maintain liver temperature
at 37°C. Perfusion was continued with oxygenated Krebs-Henseleit bicarbonate buffer
containing 20% (v/v) heparinized male rat blood at a flow rate of 20 ml/min (80 ml, total
volume). Livers and perfusate were allowed to acclimate 10 min before addition of 26 μg/ml
silymarin. Liver viability was assessed by monitoring portal pressure (<15 cm of H2O),
observing gross morphology, and measuring initial bile flow in WT and TR- IPRLs (>0.8 and
>0.3 μl/min/g liver, respectively). Taurocholate (0.5 μmol/min, in saline) was infused into the
perfusate reservoir to maintain bile flow. Bile was collected continuously at 10-min intervals,
and the volume was determined gravimetrically (specific gravity 1.0). Perfusate (0.5 ml) was
sampled every 10 min and immediately centrifuged to obtain supernatant for analysis. After
perfusion, livers were blotted dry and weighed. All samples collected from this experiment
were stored at -80°C until further analysis.
Analysis of Silymarin Flavonolignans in Perfusate and Bile
Identification and quantification of silymarin flavonolignans in the perfusate and bile was
carried out by LC-ESI-MS using a previously established method with slight modifications
(Wen et al., 2008). Briefly, separation of silymarin flavonolignans was performed using an
Agilent HP 1100 LC system with a C18 SecurityGuard cartridge (4 × 2.0 mm i.d.; Phenomenex,
Torrance, CA) and a Luna C18 (2) analytical column (50 × 2.0 mm i.d., 3 μm; Phenomenex,
Torrance, CA). HPLC conditions were as follows: mobile phase, methanol: 1% glacial acetic
acid (pH 2.8) (43:57, v/v) with isocratic elution; flow rate, 0.3 ml/min; injection volume, 25
μl; run time, 13 min. Typical retention times of silymarin flavonolignans SC, SD, SA, SB, ISA,
ISB, and naringenin (internal standard), under the experimental conditions were 1.8, 2.1, 4.4, ,
5.5, 7.4, 8.2, and 5.0 min, respectively. MS analysis and detection were conducted by a HP
1100 LC-MSD system (Agilent Technologies, Palo Alto, CA) with an electrospray interface
in the negative ESI ionization mode. MS parameters used for quantitative analysis were:
capillary voltage, -3500 V; fragmentor voltage, 150V; drying gas temperature, 350 °C;
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nebulizer gas pressure, 35psig; drying gas flow, 8 l/ml; scan mode, selective ion monitoring
(SIM) with [M-H]- for silymarin flavonolignans (m/z 481), silymarin sulfates (m/z 561),
silymarin glucuronides (m/z 657), and naringenin (m/z 271), respectively. Split calibration
curves for the free (unconjugated) and total (unconjugated plus conjugated) flavonolignans in
the concentration range of 10-500 ng/ml and 500-10,000 ng/ml were generated using reference
standards of SC, SD, SA, SB, ISA and ISB. Mixed standard solutions containing SC, SD, SA,
SB, ISA, and ISB were spiked into blank perfusates and bile treated as described in the perfusate
and bile sample preparation (see below). Concentrations of silymarin flavonolignans in the
samples were estimated with 1/x2 weighted least-squares regression equations derived from
the peak area ratios of individual silymarin flavonolignans to that of the internal standard. The
limit of detection was 5 ng/ml and limit of quantification for the silymarin flavonolignans was
10 ng/ml. Intra- and inter-day precisions were 1.7 - 11%, and 4.5 - 14%, respectively.
Perfusate and bile samples were initially diluted 1:5 and 1:50, respectively. Aliquots of
perfusate and bile samples as well as blank perfusate and bile spiked with standards of SC, SD,
SA, SB, ISA and ISB, were protein-precipitated by the addition of 300 μl of ice-cold acetonitrile
and 1% glacial acetic acid containing internal standard, naringenin (200 ng). After the removal
of protein by centrifugation at 15,000g for 15 min at 4°C, the supernatants were transferred
and evaporated with a gentle stream of nitrogen at 45°C in a water bath. The residue was
reconstituted in 100 μl of the HPLC mobile phase and centrifuged at 10,000g for 10 min at 4°
C; 25 μl of the reconstituted supernatants were introduced for LC-ESI-MS analysis.
Enzyme Hydrolysis of Sulfate and Glucuronide Conjugates of Silymarin
Concentrations of sulfated, glucuronidated, and total (unconjugated and conjugated) silymarin
flavonolignans in perfusate and bile were measured after hydrolysis with sulfatase, β-
glucuronidase and a mixture of sulfatase and β-glucuronidase, respectively (Wen et al.,
2008). Unconjugated silymarin flavonolignan concentrations in perfusate and bile were
directly determined without enzyme hydrolysis. Conjugated silymarin flavonolignan
concentrations were determined as the difference between total (determined with enzyme
hydrolysis) and unconjugated (without enzyme hydrolysis) and expressed as parent equivalents
of silymarin flavonolignans. Briefly, aliquots of 100 μl diluted perfusate and bile were treated
with sulfatase (80 U/ml in the final incubation) containing D-SL (10mM), β-glucuronidase
containing 0.1 M phosphate buffer (8000 U/ml in the final incubation), and a mixture of
sulfatase (80 U/ml) and β-glucuronidase (8000 U/ml), respectively. The individual mixtures
with different hydrolytic enzymes were buffered by 0.25 M sodium acetate (pH 5.0) and
incubated (final volume 120 μl) at 37°C with gentle shaking for 6 h. The reactions were
terminated by the addition of 300 μl of ice-cold acetonitrile containing 1% glacial acetic acid
and internal standard naringenin (200 ng). After the removal of protein by centrifugation at
15,000g for 15 min at 4°C, the supernatants were evaporated and treated as described in the
analysis of silymarin flavonolignans in perfusate and bile; the final reconstituted samples were
analyzed by LC-ESI-MS.
Pharmacokinetics and Statistical Analyses
The six major flavonolignans comprised 2.08 mg or 53.88% of the 3.86 mg milk thistle extract
added to the 80 ml of perfusate. Initial quantities of the six flavonolignans added to the perfusate
were as follows: 470 μg of silychristin, 188 μg of silydianin, 443 μg of silybin A, 726 μg of
silybin B, 172 μg of isosilybin A and 81 μg of isosilybin B (Wen et al., 2008). Thus, the initial
total perfusate concentration of flavonolignans was 26 μg/ml. All data are expressed as mean
± S.E.M, from three individual experiments. Pharmacokinetic parameters for individual
silymarin flavonolignans (unconjugated and conjugates, respectively) were calculated using
WinNonlin 4.1 (Pharsight Corporation, Mountain View, CA). The individual unconjugated
silymarin flavonolignan concentrations over 90 min in the perfusate and extrapolated to infinity
Miranda et al. Page 4













were used to calculate the clearance (CL) from the perfusate, and the estimated initial perfusate
concentration (C0), using a non-compartmental i.v. model. The area under the curve during the
90-min perfusion (AUC0→90 min) was calculated according to the log-linear trapezoidal rule.
Biliary clearance (Clb) for each silymarin flavonolignan during the 90-min collection interval
was calculated as the cumulative amount of unconjugated flavonolignan excreted in the bile
(Ae) divided by the perfusate AUC0→90 min of the unconjugated flavonolignans. Apparent
hepatobiliary clearance of conjugated silymarin flavonolignans was defined as the cumulative
amounts of conjugated flavonolignans excreted into the bile (Ae) divided by the plasma
AUC0→90 min for each of the flavonolignans. The following assumptions are included in the
definition of hepatobiliary clearance: 1) conjugates excreted into the perfusate return to the
liver for biliary excretion; and 2) there is no competition between flavonolignans and
flavonolignan conjugates for biliary excretion. Thus, the apparent hepatobiliary clearance
encompasses the formation clearance to conjugates that are ultimately excreted in bile as well
as biliary excretion of conjugates. Statistical differences between WT and TR- IPRL data were
assessed using ANOVA followed by Student’s t-test at a significance level of p<0.05.
Results
Pharmacokinetics of Silymarin Flavonolignans in Isolated Perfused Rat Liver
Pharmacokinetic parameters describing the disposition of the six major silymarin
flavonolignans in the WT and TR- IPRLs during the 90-min perfusion are presented in Table
1. In addition, the complete concentration-time profiles from which pharmacokinetic data were
obtained for silybin A and silybin B are depicted in Figure 1, since they comprise approximately
60% of the total flavonolignans in silymarin extracts and are the most well studied
flavonolignans in vivo. As shown in Figure 1, similar perfusate concentration-time profiles
were obtained from WT and TR- IPRLs; approximately 97% of silybin A and silybin B were
cleared from the perfusate by 30 min. Similar concentration-time profiles also were observed
for silychristin, silydianin, isosilybin A and isosilybin B in both WT and TR- IPRLs (data not
shown). When the extrapolated initial perfusate concentrations (C0) for each of the six
flavonolignans were summed, the total concentration of silymarin flavonolignans in the
perfusate amounted to 21.9 μg/ml for WT and 21.3 μg/ml for TR- IPRLs, which were
comparable to the theoretical perfusate silymarin concentration of 26 μg/ml at the start of each
perfusion. Consistent with the concentration-time profiles, no significant differences in the
clearance of each silymarin flavonolignan from the perfusate were observed between WT and
TR- IPRLs. These data suggest that the exposure of WT and TR- IPRLs to each flavonolignan
was similar, allowing for mass-balance comparisons.
Concentration-time Profiles of Flavonolignan Conjugates in Perfusate
Concentration-time profiles for silybin A and silybin B conjugates in the perfusate are shown
in Figure 2A and 2B, respectively. After an initial lag time of about 6 min, concentrations of
flavonolignan conjugates increased rapidly in perfusate and reached a plateau after ∼ 50 min.
The concentrations of silybin A and silybin B as conjugates in the perfusate of WT IPRLs at
90 min was 1.2 μg/ml and 1.9 μg/ml, respectively, or approximately 21-22% of the initial dose
of the parent flavonolignans. Similar concentration-time profiles were observed for the other
flavonolignans (data not shown). Perfusate conjugate concentrations of isosilybin A (0.6 μg/
ml), isosilybin B (0.1 μg/ml), silychristin (0.3 μg/ml) and silydianin (0.1 μg/ml) at 90 min
accounted for approximately 28%, 10%, 5%, and 4% of the dose for each flavonolignan,
respectively.
In contrast to WT IPRLs, approximately 78-80% of the dose for silybin A and silybin B was
excreted into perfusate as conjugates at 90 min in TR- IPRLs. Similar conjugate concentration-
time profiles were observed for the other flavonolignans (data not shown).
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Biliary Excretion of Silymarin Flavonolignans and Flavonolignan Conjugates
Representative cumulative biliary excretion profiles of silybin A and silybin B conjugates by
WT and TR- IPRLs are shown in Figures 3A and 3B, respectively. Similar biliary excretion
profiles also were obtained for silychristin, silydianin, isosilybin A and isosilybin B (data not
shown). For WT IPRLs, the cumulative biliary excretion profiles for silybin A and silybin B
revealed a time lag between 10 to 20 min after which the amount of flavonolignan conjugates
excreted into bile rose rapidly until 40 min. This lag period coincided with the 20-min period
where most of the silybins are extracted from the perfusate and into the liver (see Fig.1.), and
flavonolignan conjugate concentrations plateau in the perfusate (see Fig.2.). Also depicted in
Figure 3 are the cumulative biliary excretion profiles for silybin A and silybin B conjugates
during perfusions of TR- livers. Perfusate concentrations of silybin conjugates rose more
rapidly during the first 20 min of the perfusion compared to that observed with WT IPRLs (see
Fig.2.). Only, 2.5% and 4% of the doses for silybin A and silybin B, respectively, were excreted
into bile as conjugates in TR- IPRLs at 90 min compared to 21% and 32%, respectively, with
WT IPRLs. In addition, the biliary excretion profiles for silychristin, silydianin, isosilybin A
and isosilybin B also were significantly reduced in TR- livers (data not shown).
For WT livers, 7.2 μg of silychristin, 2.6 μg of silydianin, 2.9 μg of silybin A, 3.5 μg of silybin
B, 0.5 μg of isosilybin A, and 0.3 μg of isosilybin B were excreted unchanged into the bile at
the end of the 90-min perfusion. Similar amounts of each flavonolignan also were excreted
into the bile by TR- IPRLs, and no differences in the biliary clearances of the unconjugated
flavonolignans between livers from WT and TR- rats were evident (Table 1). These data suggest
that biliary excretion of the parent flavonolignans may not be mediated by Mrp2.
Figure 4A depicts the cumulative percentage of the dose excreted in bile through 90 min as
conjugates in WT and TR- IPRLs for each of the six silymarin flavonolignans. For WT livers,
242.7 μg of silychristin, 190.8 μg of silydianin, 93.1 μg of silybin A, 230.3 μg of silybin B,
86.9 μg of isosilybin A, and 34.7 μg of isosilybin B were excreted in the bile as conjugates at
the end of the 90-min perfusion. Compared to WT IPRLs, the biliary excretion of flavonolignan
conjugates was reduced by 80% to 92% in TR- IPRLs (silychristin, 86%; silydianin, 92%;
silybin A, 88%; silybin B, 88%; isosilybin A, 82%; and isosilybin B, 80%). These results
suggest that the biliary excretion of flavonolignan conjugates is primarily dependent on Mrp2.
Figure 4B summarizes the percentage of the dose recovered as conjugates (glucuronide and
sulfate) in the perfusate after 90-min in both WT and TR- IPRLs for each of the six silymarin
flavonolignans. Among the flavonolignans, between 30% to 83% of the administered dose was
excreted into the perfusate in TR- IPRLs compared to only 5% to 30% of the dose in WT IPRLs.
Silychristin conjugates exhibited the greatest increase in perfusate exposure in TR- IPRLs.
However, the total amount of flavonolignan conjugates (glucuronides and sulfates) excreted
in both bile and perfusate after 90-min was not different between TR- IPRLs (1552.8 μg ±
321.6) and WT IPRLs (1227.1 μg ± 265.3).
The total recovery of the 2.08 mg perfusion dose of silymarin flavonolignans ranged between
50 to 74% for WT IPRLs (mean 1.26 ± 0.26 mg), and between 64 to 91% (mean 1.60 ± 0.28
mg) for TR- IPRLs. Another 7 to 9% of the silymarin flavonolignan dose was recovered in
three perfused livers that were examined (data not shown). These data suggest that the major
effect of Mrp2 deficiency on the excretion of flavonolignan conjugates in rat IPRLs is a shift
in excretion from bile to the perfusate.
Cumulative Biliary Excretion of Silymarin Glucuronide and Sulfate Conjugates
To determine whether the extent of biliary excretion of each silymarin flavonolignan was
governed by the type of conjugation reaction, the cumulative biliary excretion of flavonolignan
glucuronide and sulfate conjugates was determined. As shown in Figure 5 in the WT IPRLs,
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the primary route of conjugation for silydianin was by glucuronidation (80.5%) while sulfation
was the major pathway for silybin B (78%), isosilybin A (84%) and isosilybin B (85%).
Approximately equal amounts of glucuronide and sulfate conjugates were recovered in bile
for silybin A and silychristin. These data suggest that each silymarin flavonolignan has a
preferred route of phase II metabolism. Also depicted in Figure 5 is the cumulative biliary
excretion of glucuronide and sulfate conjugates for each flavonolignan by TR- IPRLs, which
were significantly reduced irrespective of the type of conjugation reaction. Compared to WT
IPRLs, the amount of glucuronide and sulfate conjugates for each of the flavonolignans
excreted into bile was reduced between 94-98% and 73-84%, respectively, in TR- IPRLs.
The apparent hepatobiliary clearances for the six flavonolignans are summarized in Table 2.
Consistent with the data presented in Figure 5, hepatobiliary clearances for both glucuronide
and sulfate conjugates of each silymarin flavonolignan were markedly reduced by ∼ 89-99 %
and 75-90%, respectively, in TR- compared to wild-type IPRLs. The apparent hepatobiliary
clearances for silydianin more closely reflect its formation clearance since this flavonolignan
is almost completely excreted in the bile. Collectively, these data indicate for the first time a
significant role of Mrp2 in biliary elimination of glucuronide and sulfate metabolites of each
of the six silymarin flavonolignans.
Discussion
In the present study, we compared the hepatobiliary disposition of silymarin using isolated
perfused livers from WT and TR- rats. The initial perfusate concentration of total silymarin
flavonolignans used in this study (26 μg/ml) was within the range of plasma concentrations
for total flavonolignans attained in vivo with oral dosing. Peak concentrations of silybin A and
B between 0.06 μg/ml with silymarin doses of 200 mg/kg (Morrazoni et al., 1993) and 9.02
μg/ml with silipide doses of 200 mg/kg (Morrazoni et al., 1992, Morrazoni et al., 1993) have
been observed in pharmacokinetic studies in rats. Concentrations of silybin A and B as high
as 10-40 μg/ml have been observed in clinical studies (Flaig et al., 2007).
High first-pass phase II metabolism is believed to be the major factor responsible for the poor
bioavailability of silymarin in man, since glucuronide conjugates account for approximately
90% of the total amount of silybin A and silybin B in blood following oral doses (Gatti and
Perucca, 1994; Weyhenmeyer et al., 1992). In rats, glucuronide and sulfate conjugates
accounted for 98% of silybin A and silybin B in blood and bile (Morrazoni et al., 1992;
Morrazoni et al., 1993). In humans, silymarin conjugates are excreted primarily into bile since
less that 5% of the dose is excreted in urine (Weyhenmeyer et al., 1992). In addition, reduced
clearance of silybin conjugates, consistent with impaired biliary excretion of conjugates, was
observed in patients with extrahepatic biliary obstruction (Schandalik et al., 1992). In our study,
all six silymarin flavonolignans were cleared rapidly from the perfusate, and up to 100% of
silymarin flavonolignans were excreted as conjugates into bile at the end of the 90-min
perfusion. Although between 70-85% of the total dose was recovered in perfusate, bile, and
perfused liver, conclusions regarding mass balance in our study cannot be stated with certainty
given the high variability observed with IPRL studies. It is possible that formation of additional
metabolites may account for a portion of the dose since the silymarin concentration used in
our study has been associated with the formation of cytochrome P450-catalyzed demethylated
and hydroxylated products in vitro (Jančová et al., 2007; Gunaratna and Zhang, 2003).
While the specific transport proteins involved in the elimination of silymarin and its conjugates
have not been identified, previous studies have shown that silymarin has inhibitory effects on
the active transport of drugs mediated by Pgp, Mrp1, Mrp4 and Mrp5 (Zhang and Morris,
2003; Nguyen H et al., 2003; Lania-Pietrzak B et al., 2005; Wu CP et al., 2005; Wu et al.,
2008). However, there have been no direct investigations of the biliary excretion of silymarin
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and its conjugates, which could present a complex problem since each of the six major silymarin
flavonolignans could have different affinities for the various hepatobiliary transport proteins.
Mrp2 is a canalicular organic anion transport protein that is responsible for the biliary
elimination of organic anions such as the anticancer drug methotrexate (Luo et al., 2007). Mrp2
also has been shown to be an important transport protein for the biliary excretion of
polyphenolic natural products such as quercetin (van Zanden et al., 2007), resveratrol (Maier-
Salamon et al., 2008), and 4-methylumbelliferone (Zamek-Gliszczynski et al., 2006b). To
establish the dependence of silymarin flavonolignans on Mrp2 for biliary excretion, the present
studies were conducted in isolated perfused livers from Mrp2-deficient TR- rats, which are
naturally occurring mutants of the Wistar rat (Jansen et al., 1985; König et al., 1999). TR- rats
have hereditary conjugated hyperbilirubinemia and exhibit elevated bile acid concentrations,
reduced bile flow, up-regulation of basolateral transport protein Mrp3, and display impaired
biliary excretion of most organic anions. Livers from TR- rats also exhibit negligible biliary
excretion of glucuronide and glutathione conjugates, whereas biliary excretion of sulfate
conjugates may only be partially impaired (Maier-Salamon et al., 2008). Our study using
isolated perfused livers from TR- rats indicated that Mrp2 is the major canalicular transport
protein involved in the biliary excretion silymarin flavonolignan conjugates. Although biliary
excretion of the parent silymarin flavonolignans remained unchanged in the TR- and WT
IPRLs, the rapid phase II metabolism to glucuronide and sulfate conjugates may limit their
availability for active transport. For each parent flavonolignan, < 5% of the dose was recovered
in bile as unchanged flavonolignan at the end of each perfusion in both WT and TR- IPRLs,
indicating that other canalicular transport proteins such as Pgp or Bcrp may mediate high
affinity transport.
The basolateral organic anion transport protein, Mrp3, is upregulated as a compensatory
mechanism for the absence of Mrp2 in TR- rats (Ogawa et al., 2000; Johnson et al., 2006.). In
TR- rats, increased basolateral efflux of methotrexate (Luo et al., 2007), gemfibrozil (Kim et
al., 2003), acetaminophen glucuronide (Xiong et al., 2002) which are Mrp2 substrates, have
been observed. During the first 30 minutes of the perfusion when parent flavonolignans were
almost completely extracted from perfusate by both TR- and WT IPRLs, the rate of appearance
of silybin A and silybin B conjugates in the perfusate was significantly greater for TR-
compared to WT IPRLs. While this increase in basolateral efflux of flavonolignan conjugates
in TR- rats is consistent with an upregulation of Mrp3, redirection of flavonolignan conjugates
from canalicular to basolateral excretory pathways would be expected to occur in TR- rats due
to the loss of Mrp2.
Information on the influence of phase II conjugation pathways on the biliary excretion of
natural products is limited. Structural rather than stereo differences between the flavonolignans
appeared to have the greatest influence on the extent of biliary elimination observed in our
study. However, the finding that silydianin was the only silymarin flavonolignan that was
primarily glucuronidated and almost completely excreted into bile suggests that flavonolignan
glucuronide conjugates may be the preferred substrate for Mrp2. In humans, glucuronidation
appears to be a preferred pathway for phase II metabolism of silybin B, silydianin, isosilybin
B and silychristin (Wen et al., 2008).
In addition to Mrp2, other canalicular transport proteins may promote the biliary excretion of
sulfate conjugates in rats (Zamek-Gliszczynski et al., 2005; Zamek-Gliszczynski et al.,
2006b). For example, the biliary excretion of glucuronide conjugates of resveratrol was
decreased to a greater extent than the sulfate conjugates in TR- rats (Maier-Salamon et al.,
2008). A similar trend was noted in the present study, where biliary excretion of glucuronide
conjugates of each flavonolignan was reduced to a greater extent in TR- IPRLs than the biliary
excretion of sulfate conjugates.
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An important finding from our study was that the conjugates of silydianin were almost
exclusively excreted into bile in the WT IPRLs, which suggests that silydianin may have the
greatest potential to undergo enterohepatic recycling. In addition, the almost complete recovery
of the dose for silydianin as glucuronide conjugates in the bile of WT IPRLs, which was reduced
by ∼ 92% in TR- rat livers, suggests that this flavonolignan may be useful as a probe substrate
for assessing changes in the functional activity of Mrp2. Many transport proteins of the ABC
family such as MRP2 appear to be down-regulated in the livers of patients with chronic HCV
(Hinoshita et al, 2001). In addition, while other studies have failed to demonstrate changes in
expression detected by immunohistochemical techniques, there appears to be differences in
the extent of recycling of canalicular transporters between the canalicular membrane and
intracellular pools (Ros et al., 2003) in liver disease. Also, upregulation of basolateral efflux
transport proteins such as MRP3, MRP4 and MRP5 has been observed in liver diseases as an
adaptation to the reduced expression of MRP2 (Ros et al., 2003; Barnes et al., 2007). Therefore,
a specific MRP2 probe substrate would be useful for quantitating the extent of changes in
functional activity irrespective of the expression of total MRP2 protein in diseased liver.
Given the results presented here, which indicate a primary role for Mrp2 in the biliary
elimination of silymarin flavonolignan conjugates, it is likely that liver disease may be
associated with down-regulation of MRP2 in humans since higher plasma concentrations of
silymarin conjugates have been observed in patients with liver disease compared to healthy
volunteers (Schrieber et al., 2008a). Similar changes in the disposition of silybin A and B have
been reported by Wu et al, 2008 utilizing a rat model of cirrhosis where an approximately two-
fold increase in plasma AUC for silybin A and B conjugates was correlated with a 50%
reduction in the bile to blood exposure ratio for total silybin A and B in cirrhotic rats compared
to control. In addition, phase II metabolites of silychristin and silydianin may have greater
specificity for Mrp2 since in this study their conjugates were the most extensively excreted
into bile among the six major flavonolignans. A recent observation that among the six
flavonolignans, enterohepatic recycling was only observed for the conjugates of silychristin
and silydianin in patients with chronic HCV (Schrieber et al., 2008b), suggests that these two
flavonolignans may be useful as surrogate markers of functional changes in MRP2 activity. In
humans, decreased biliary excretion of flavonolignan conjugates may potentially influence the
efficacy of silymarin due to down-regulation of MRP2 and reduced enterohepatic recycling
and return of parent flavonolignans in portal blood.
In summary, these data indicate a primary role for Mrp2 in the biliary excretion of silymarin
flavonolignan conjugates. Hepatic expression of MRP2 may be altered by chronic liver disease.
The finding that silydianin is primarily glucuronidated and excreted into bile suggests that it
might serve as a specific MRP2 probe substrate for quantitating functional changes in MRP2
activity resulting from liver disease. The extent to which, alterations in MRP2-mediated biliary
excretion of silymarin flavonolignans influence the antioxidant or antiviral activity of silymarin
warrants investigation.
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HCV, hepatitis C virus
Mrp, multidrug resistance associated- protein
Bcrp, breast cancer resistance protein
WT, Mrp2-competent
TR-, Mrp2-deficient
IPRL, isolated perfused rat liver
LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry
AUC0→90, area under the plasma concentration-time curve from time 0 to 90 min
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Perfusate concentration versus time profiles of unconjugated silybin A (A) and silybin B (B)
in isolated perfused livers from wild-type (•) and TR- (○) rats. Silymarin (26 μg/ml) was added
to the recirculating perfusate reservoir and livers from male Wistar rats were perfused for 90
min. Concentrations of silybin A and silybin B were determined by LC-MS analysis as
described in Materials and Methods. Data are expressed as mean of n=3 livers in each group;
mean ± S.E.M at the 90-min timepoint.
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Perfusate concentration versus time profiles of silybin A (A) and silybin B (B) conjugates
(glucuronide + sulfate) in isolated perfused livers from wild-type (•) and TR- (○) rats. Silymarin
(26 μg/ml) was added to the recirculating perfusate reservoir and perfusate samples were treated
with or without a mixture of β-glucuronidase and sulfatase to obtain the total and unconjugated
flavonolignan concentrations, respectively. Perfusate conjugate concentrations of silybin A
and silybin B were determined as the difference between the total and unconjugated
concentrations for each flavonolignan. Data are expressed in equivalents of the unconjugated
flavonolignans as mean of n=3 livers in each group; mean ± S.E.M at the 90-min timepoint
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Cumulative biliary excretion of silybin A (A) and silybin B (B) conjugates (glucuronide +
sulfate) in isolated perfused livers from wild-type (•) and TR- (○) rats. Data are expressed in
equivalents of the unconjugated flavonolignans as mean of n=3 livers in each group; mean ±
S.E.M at the 90-min timepoint.
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Cumulative excretion of conjugated (glucuronide + sulfate) silymarin flavonolignans in bile
(A) and perfusate (B) at 90 min in isolated perfused livers from wild-type and TR- rats. Data
are expressed in equivalents of the unconjugated silymarin flavonolignans as mean ± S.E.M
of n=3 livers in each group; *, p<0.05, WT vs TR-.
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Cumulative biliary excretion of the glucuronide and sulfate conjugates of silymarin
flavonolignans in isolated perfused livers from wild-type and TR- rats. Data are expressed in
equivalents of unconjugated silymarin flavonolignans as mean ± S.E.M of n=3 livers in each
group; *, p<0.05, WT vs TR- for glucuronide conjugates; †, p<0.05, WT vs TR- for sulfate
conjugates.
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